CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Zoledronic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00049829
NCT00049829Phase 3Completed
CompareCT.gov

HORIZON-PFT: Pivotal Fracture Trial

Novartis Pharmaceuticals·interventional·Posted Nov 15, 2002·Updated Nov 2, 2011

In Brief

A Phase 3 clinical trial evaluating Zoledronic Acid for Osteoporosis. Completed, across 60 sites in 2 countries.

Detailed Summary

HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesGermany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 15, 2002
Enrollment StartJan 1, 2002
Primary CompletionJun 1, 2006
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 23.6 years ago

Interventions

Zoledronic Aciddrug